19 December 2012

Japanese stem cell technology company ReproCELL opens U.S. office in Boston

- New office currently employs three people
- Plans to hire an additional nine employees by 2016 
- ReproCELL is based in Yokohama, Japan

Boston – 18 December 2012 – ReproCell, Inc., a Japanese stem cell technology company, and the Massachusetts Life Sciences Center (MLSC) today announced the opening of the company’s first branch and U.S. office in Boston. ReproCELL is the fourth company that has announced plans for a Massachusetts office after meeting with the MLSC and other state partners at the recent BIO International Convention in Boston this past June. ReproCELL is also the third Japanese life sciences company to announce plans for expansion into Massachusetts in the past six months, following Scivax and HMT. 

The new office currently employs three people, with plans to hire an additional nine employees by 2016. ReproCELL is based in Yokohama, Japan. 

“The U.S. market is the most important for ReproCELL to enter in order to foster our growth -- we estimate that the U.S. market is 20 to 50 times larger than that of Japan,” said Takashi Masai, COO, ReproCELL USA. “Massachusetts is the perfect place to start our business in the U.S. because of its high concentration of top-level customers for both of our business lines. In addition, the Commonwealth provides access to the network of biotech professionals and support from government partners, such as the MLSC.” 

Founded in 2003, ReproCELL is the only Japanese human embryonic stem (ES) and induced pluripotent stem (iPS) cell-related company. ReproCELL offers the following product lines: human iPS/ES cell culture media and the world’s first commercialized human iPS cell derived cardiomyocyte, dopaminergic neuron, cholinergic neuron, Alzheimer’s disease model neuron and hepatocyte. In October, the company was included on the “Deloitte Technology Fast 50 Japan” list. 

“Thanks to our growth strategy of investing in education, innovation and infrastructure, including our 10-year, $1-billion Life Sciences Initiative, Massachusetts continues to lead the world in life sciences,” said Governor Deval Patrick. “I congratulate ReproCELL, and appreciate the company’s commitment to growing in Massachusetts.” 

Massachusetts is home to groundbreaking work in stem cell research and development, and we are proud that one of Japan’s leading stem cell companies has chosen the Commonwealth as its U.S. base of operations. As the third Japanese life sciences organization to announce plans for a Massachusetts location in the past six months, ReproCELL is in very good Company,” said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC, the agency charged with implementing Governor Patrick’s 10-year, $1 billion Life Sciences Initiative. 

Source: ReproCELL and MLSC